(NASDAQ: ATAI) Ataibeckley's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.62%.
Ataibeckley's earnings in 2026 is -$660,047,000.On average, 16 Wall Street analysts forecast ATAI's earnings for 2026 to be -$174,859,225, with the lowest ATAI earnings forecast at -$275,237,320, and the highest ATAI earnings forecast at -$134,044,149. On average, 14 Wall Street analysts forecast ATAI's earnings for 2027 to be -$170,445,799, with the lowest ATAI earnings forecast at -$253,790,256, and the highest ATAI earnings forecast at -$137,873,982.
In 2028, ATAI is forecast to generate -$185,290,960 in earnings, with the lowest earnings forecast at -$275,237,320 and the highest earnings forecast at -$111,065,152.